ImetelChat

If there are some "super vibes" for Rytelo at ASH2024 they are likely to come from ferroptosis, longevity and AML. The AML presentations of Bruedigam (Dec. 7 - oral), Platzbecker (Dec.8 - poster), and Stevens (Dec. 9 - extra) will be closely watched. ======== Extra Review, AML Forward Looking ---- ...

My thought --- Why would Geron have a fireside chat with investment bankers, unless they had some very positive information for these people? These 3 presentations seem to tie together ferroptosis and AML. We will know tomorrow if there is important new information, or only good weather in Coral Ga...

Back to back: Financial/PPS (Evercore) & Medical/Science (ASH2024) 1/ Fireside chat on December 4 (Evercore) for the investment community 2/ ASH2024 December 7 to 9 (6 presentations --3 oral & 3poster) + 1 forward looking informational session (AML/MF/MDS) — medical science (adult & children) It ap...

This informal presentation is a heads-up about Rytelo combinations and things that are coming in 2025 -- a planned research and clinical trial project in the field of pediatric blood cancers. Background information Dr. Alexandra M. Stevens MD Pediatric Hematology-Oncology Texas Children's Hospital ...

This seems to be a 3rd type of presentation: 1/ Oral (3) 2/ Poster (3) 3/ Informal (1) This informal presentation is timely and fits in nicely with the 2 AML presentations (oral & poster) and the current interest in ferroptosis . This certainly is positive looking ahead. ============ A Pediatric Ear...

Kmall --- Is this a 7th Rytelo/Imetelstat presentation for ASH2024? What is the abstract number?

Evercore is a premier global independent investment banking firm dedicated to helping clients achieve superior results. www.evercore.com This is a fireside chat for the investment banking industry. Geron must have something important to say, from an investment point of view. ============== Founded ...

December one, two, three punch 1/ Fireside chat on December 4 2/ ASH2024 December 7 to 9 (6 presentations) 3/ After ASH-- Approvals from the EMA and MHRA/UK (hopefully before the New Year) Rytelo is in the spotlight. December will be filled with news about Rytelo. Hopefully this will satisfy the in...

Considering the quality of the presenters, and their prestige as KOLs, I see only "good vibes" coming from ASH2024 for Rytelo. Perhaps there will be some "super vibe" that we are not expecting. PT by Uwe Platzbecker, M.D., Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Di...

The questions have always been: 1/ How good is Rytelo now as a single agent? Should find out at ASH2024 2/ How good is Rytelo in combinations, in cancers beyond blood cancers and as an adjunct to chemotherapy? Probably need EMA approval before seriously continuing new research with significant new f...

RYTELO (AML, MDS, MF)--- 6 ASH2024 presentations from cancer experts from all over the world (USA, Australia, Europe) from Dec. 7 to 9. Looks very important, interesting and impressive. The presenters are world class oncology experts (KOLs).

I have always thought that if Rytelo gets approved by the FDA (done), the EMA (pending) and the MHRA/UK (pending), then Geron is in the driver's seat and can shape themselves as an independent company with strategic partners in the USA and Europe. Some have called this the Amgen model. With 6 import...

"Good Vibes" --- Rytelo is an exceptional blood cancer medicine, which will be reenforced by 6 presentations on December 7-9 at ASH2024 (AML, MF, MDS ---3 oral, 3 posters). "Bad Vibes" --- Geron's PPS is now being influenced by the unknown future of the FDA, which now appears to be rather grim in t...

The "good vibes" from the ASH2024 abstracts continue as we await the conference starting December 7. However, all biotech stocks (PPS) are being affected by the "bad vibes" coming from a potential dysfunctional FDA in 2025. 3 Oral Presentations (ASH2024): Abstract #52:-- Oral presentation on Saturd...

Ryan -- Certainly, Geron's current PPS is a "bad vibe". However, much of the investment community is upbeat (see example). There are many other examples (Wainwright, Goldman Sachs, etc.) ========================== MarketBeat https://www.marketbeat.com/stocks/NASDAQ/GERN/forecast Geron (GERN) Stock ...

We are in a waiting game now. As I see it, the Rytelo vibes are mostly very "good vibes". I don't see any "bad vibes" at the moment, with ASH2024 (Dec. 7) and European approvals soon. I cannot see beyond that. The value of Geron is set by the investment community including Goldman Sachs and the 26 ...

Both November 5th and November 7th look very positive medically and scientifically. The next hurdles are the full papers at ASH2024 (December 7th) and approvals from Europe (EMA and MHRA/UK). Together, I believe, jumping these hurdles successfully will propel Geron's PPS much higher. We need those ...

The Good Vibes continue: FOSTER CITY, Calif.--(BUSINESS WIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2024 and recent business highlight...

Ferroptosis, killing cancer stem cells, AML, Geron collaborators, synergies This may be the most important paper for Rytelo at ASH2024. Ferroptosis is an exceptional feature of Rytelo (a 2nd way to get at and kill cancer stem cells) that is new and not well understood, at this point in time. ======...

I am impressed with the diversity of the ASH2024 abstracts. This is the beginning of many "good vibes". There is more to come on November 7 (Rytelo updates on demand, distribution and interest). There is much to mull over, as the world learns about Geron and Rytelo (medicine, investment, future pot...